AIM ImmunoTech Inc. (AIM) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 3 Buy.
Analysts estimate Earnings Per Share (EPS) of $-29.97 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.31 vs est $-29.97 (beat +99%). 2025: actual $-8.62 vs est $-7.74 (missed -11.3%). Analyst accuracy: 0%.
AIM Analyst Ratings
Buy
Based on 3 analysts giving stock ratings to AIM ImmunoTech Inc. in the past 3 months
EPS Estimates — AIM
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.31
vs Est –$29.97
▲ 9,567.8% off
2025
Actual –$8.62
vs Est –$7.74
▼ 10.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — AIM
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▼ 17.6% off
2025
Actual $0.000B
vs Est $0.000B
▼ 13.6% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
